Degarelix

• Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending
  2023-503676-25-01 Phase II 1 country Azienda Provinciale Per I Servizi Sanitari
• ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with p… Pending
  2024-517285-41-00 Phase III 1 country ARTIC
• Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression – the PREVENT-M… Pending
  2024-518120-68-01 Phase II 1 country Vaestra Goetalandsregionen
• Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial Recruiting
  2022-501551-90-00 Phase II/III 2 countries Ziekenhuis Aan De Stroom
• A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting
  2025-521859-23-00 Phase I/II 4 countries Novartis Pharma AG
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting
  2024-520156-22-00 Phase II 7 countries Novartis Pharma AG
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 Phase III 9 countries European Organisation For Research And Treatment Of Cancer
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting
  2023-507482-26-00 Phase III 4 countries Unicancer
• Prostate medication, metabolism and gut microbiota, PROMED. Recruiting
  2022-500618-24-00 Phase IV 1 country Turku University Central Hospital
• Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting
  2022-502373-42-00 Phase III 1 country UZ Leuven
• The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic pros… Recruiting
  2024-519516-14-01 Phase II 1 country Turku University Hospital
• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended
  2024-511038-11-00 Phase II 7 countries Debiopharm International SA
• A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) w… Ended
  2024-512023-37-00 Phase II 1 country Ziekenhuis Aan De Stroom
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended
  2022-503040-41-00 Phase II 7 countries Novartis Pharma AG
• SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended
  2023-507672-52-00 Phase I (FiH) 1 country Novartis Pharma AG
• Neoadjuvant ADT with TULSA Ended
  2022-502067-38-00 Phase I (Other) 1 country Turku University Central Hospital
• A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 versus 2-weekly Docetaxel 50 mg/m2 in combination with Darolutamide + ADT … Ended
  2022-502634-52-00 Phase III 2 countries Friedrich-Schiller-Universitaet Jena
• DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended
  2023-509494-23-00 Phase II 1 country Institut Bergonie
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended
  2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-506365-64-00 Phase III 13 countries Janssen - Cilag International
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-503254-12-00 Phase III 10 countries Janssen - Cilag International
• A research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-ris… Ended
  2024-513450-30-00 Phase III 3 countries Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…

Showing 1–22 of 22 trials